Full-Time

Full-Stack AI Engineer / Data Scientist

Agentic Systems

Updated on 8/20/2026

Deadline 8/25/26
Roche

Roche

1-10 employees

Global pharmaceuticals and diagnostics company

No salary listed

Hyderabad, Telangana, India

In Person

Occasional work across Central European Time (CET) hours may be required.

Bachelor's, Master's, PhD

Category
Data & Analytics (1)
Required Skills
LLM
MLOps
Python
Regression
NoSQL
Data Visualization
Data Science
Graph Databases
SQL
Machine Learning
A/B Testing
Infrastructure as Code (IaC)
Docker
RAG
TypeScript
AWS
Observability
LangChain
DevOps
Data Analysis
Snowflake

Get referred to Roche

See people who can refer or advise you

Requirements
  • At least 7 years of experience in AI/ML engineering and Data Science, including exposure to generative AI, agents, and classical machine learning.
  • At least 3 years of hands-on experience with generative large language models and agents.
  • Proven experience managing the end-to-end MLOps lifecycle and deploying models at scale.
  • Proven experience leveraging AI coding agents within an agentic software development lifecycle.
  • Advanced production-grade proficiency in Python.
  • Deep expertise with LangChain or similar large language model orchestration frameworks, agentic system design, and state machine logic.
  • Practical experience designing cloud solutions on Amazon Web Services, including GenAI-specific services such as Amazon Bedrock and SageMaker.
  • Strong knowledge of vector databases, graph databases, Snowflake, SQL, NoSQL, and data lakes.
  • Expertise in API design, continuous integration and continuous delivery, Docker, Infrastructure as Code, and rigorous automated testing.
  • Strong background in statistics, data manipulation, synthetic data generation, and feature engineering.
  • Ability to define architectural patterns and step into a Tech Lead role when necessary.
  • Ability to work closely with enterprise stakeholders to consult on technological approaches to business problems.
  • Strong understanding of bias, fairness, hallucination mitigation, and responsible AI deployment.
  • Bachelor's, Master's, or PhD-level degree in Computer Science, Physics, Statistics, or Mathematics, or an equivalent qualification.
  • Ability to communicate in English at C1+ level.
  • Ability to work across Central European Time zone hours on occasion.
Responsibilities
  • Design and build advanced AI agentic systems, state machines, and search-based conversational systems for complex business problems.
  • Develop workflows using large foundational multimodal models to process and reason across text, audio, and video.
  • Implement Model Context Protocol servers and clients to standardize context exchange between agents, data sources, and external tools.
  • Collaborate with AI Architects, Product Owners, and developers to integrate AI capabilities into scalable, fair, and ethical end-user applications.
  • Use AI coding agents such as Claude Code to accelerate full-stack development across frontend, backend, and infrastructure tasks.
  • Own features end to end by writing production-ready Python and occasional TypeScript code with comprehensive testing and documentation.
  • Manage the DevOps and MLOps lifecycle by containerizing applications with Docker, configuring continuous integration and continuous delivery pipelines, and architecting reliable cloud-native solutions on Amazon Web Services and multicloud environments.
  • Perform exploratory data analysis to understand datasets, uncover patterns, detect bias, and identify data quality issues.
  • Use statistical and visualization techniques to support feature engineering, model selection, and optimization of foundation-model applications.
  • Design data pipelines to curate, preprocess, and structure diverse datasets for large language model effectiveness and bias reduction.
  • Design, customize, optimize, and fine-tune large language model-based and traditional AI algorithms for use cases such as text generation, summarization, AI agents, and sequence modeling.
  • Lead prompt engineering strategies using zero-shot and few-shot paradigms to optimize model outputs.
  • Implement classification, clustering, and regression models when they are more efficient, interpretable, or cost-effective than large language models.
  • Optimize model inference speed, reduce latency through cold-start reduction and caching strategies, and manage resource usage across cloud architectures.
  • Conduct A/B testing and implement automated metric pipelines to evaluate generative and multimodal systems.
  • Implement real-time algorithm monitoring and observability practices, including pipeline visibility, drift detection, and anomaly identification using telemetry tools.
  • Translate complex technical results into actionable insights for stakeholders and support data-driven decision-making.
Desired Qualifications
  • Additional proficiency in TypeScript.
  • Familiarity with multicloud environments.

Roche is a global leader in pharmaceuticals and diagnostics. It develops medicines and diagnostic tools that help detect, monitor, and treat diseases, using research and biotechnology to drive new therapies and tests. Roche combines drug development with in-house diagnostic products to support personalized medicine, where treatments are tailored to individual patients based on test results. Its approach differs from many peers by integrating drug discovery with diagnostic capabilities and by expanding its research through strategic acquisitions (like Genentech) to strengthen its biotechnology and R&D capabilities. The company’s goal is to improve patient outcomes and healthcare worldwide by delivering reliable medicines, accurate diagnostic tests, and data-driven care.

Company Size

1-10

Company Stage

IPO

Headquarters

Basel, Switzerland

Founded

1896

Get referred to Roche

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • H1 2026 sales rose 6% CER, with core operating profit up 10%.
  • FDA cleared cobas BV/CV and PTEN assays in July 2026, expanding diagnostics revenue.
  • CHMP recommended Susvimo in July 2026, unlocking a differentiated EU eye-care launch.

What critics are saying

  • Genentech sued Biocon July 30, 2026 over Perjeta biosimilar, signaling franchise erosion.
  • Roche faces CHF0.6 billion 2026 loss-of-exclusivity pressure, crushing slower launches.
  • Kadcyla and Ocrevus expiration timelines threaten Roche’s oncology and immunology cash engine.

What makes Roche unique

  • Roche uniquely pairs blockbuster medicines with diagnostics, selling tests alongside therapies worldwide.
  • AXELIOS 1 and PathAI deepen Roche’s moat in sequencing and AI pathology.
  • Susvimo and cobas BV/CV show Roche turns specialty science into practical platform products.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Performance Bonus

Company News

PR Newswire
Aug 6th, 2026
Roche expands cyclospora testing portfolio with three new assays for US public health labs

Roche has expanded its cyclospora testing portfolio with two new research-use-only molecular PCR tests to support U.S. public health response efforts. The LightMix Modular Cyclospora assay specifically detects cyclospora, whilst the LightMix OneTube Gastro Para 2 assay detects multiple parasites including Entamoeba histolytica, Giardia, and Cyclospora cayetanensis. Both tests work with LightCycler 480 and LightCycler PRO instruments. They complement an existing assay compatible with cobas 5800, 6800, and 8800 systems. The portfolio offers flexible testing options with one, three, or six targets. Roche acquired TIB MOLBIOL in December 2021 to expand its PCR-test capabilities for emerging infectious diseases. The company's testing infrastructure includes assays for hepatitis, HIV, respiratory illnesses, and vector-borne diseases.

PR Newswire
Jul 24th, 2026
Roche receives FDA clearance for cobas BV/CV assay for fast vaginitis diagnosis

Roche has received FDA 510(k) clearance for its cobas BV/CV assay, a molecular diagnostic test that detects bacterial vaginosis and Candida vaginitis from a single vaginal swab sample. The PCR-based test aims to improve diagnostic accuracy compared to traditional methods like microscopy and pH testing, which have misdiagnosis rates approaching 50%. Bacterial vaginosis affects approximately 27% of women of reproductive age in North America, whilst up to 75% of women experience Candida vaginitis at least once in their lifetime. The assay uses real-time PCR technology to identify specific bacteria and yeast responsible for these conditions. The test expands Roche's sexual health testing menu on its cobas 6800/8800 systems, enabling comprehensive testing for multiple conditions from a single sample. Commercial launch is expected later this year.

Yahoo Finance
Jul 24th, 2026
Roche's Susvimo receives EU approval recommendation as first continuous nAMD treatment requiring just two refills per year

Roche's Susvimo has received a positive recommendation from the European Medicines Agency's Committee for Medicinal Products for Human Use for treating neovascular age-related macular degeneration (nAMD). Susvimo is the first continuous delivery treatment that offers an alternative to standard eye injections for nAMD, requiring only two refills per year through the Contivue refillable implant. The recommendation is based on data from the LADDER, Archway and Portal studies, which showed Susvimo maintained vision equivalent to monthly intravitreal ranibizumab injections, with data supporting vision maintenance up to seven years. Approximately 95% of patients treated with Susvimo required no supplemental treatment. nAMD is a leading cause of blindness in people over 60 and affects 1.7 million in the EU. A final decision is expected from the European Commission soon.

Yahoo Finance
Jul 23rd, 2026
Roche sales grow 6% at constant exchange rates in H1 2026, led by Xolair and Hemlibra

Roche reported 6% sales growth at constant exchange rates in the first half of 2026, though this translated to a 2% decline in Swiss francs due to currency appreciation. The Swiss pharmaceutical and diagnostics company's performance was driven by strong demand for its innovative medicines and diagnostic products. The Pharmaceuticals Division grew 6% at constant exchange rates, led by Xolair, Hemlibra, Ocrevus, Phesgo, and Vabysmo. The Diagnostics Division increased 3% at constant exchange rates, driven by immunodiagnostic and clinical chemistry products. Core operating profit rose 10% at constant exchange rates. Core earnings per share grew 9% at constant exchange rates but fell 2% in Swiss francs. Key developments included multiple US priority reviews for drug candidates and positive phase III trial data. Roche also launched its Axelios 1 sequencing platform and announced an agreement to acquire PathAI. The company confirmed its 2026 outlook, expecting mid-single-digit sales growth at constant exchange rates.

Yahoo Finance
Jul 23rd, 2026
Roche appoints Dan Malarek to lead North America diagnostics business

Roche has appointed Dan Malarek as President and CEO of Roche Diagnostics North America. The leadership change affects a key operating segment within the Swiss healthcare company's business. Malarek previously led Foundation Medicine, a Roche affiliate focused on precision medicine and genomic insights. His background ties directly into themes shaping modern diagnostics use in healthcare. The diagnostics arm is central to how Roche supports hospitals, laboratories, and clinicians with testing platforms and data-driven tools. Areas such as test menu development, data integration with pharmaceuticals, and health system partnerships are potential focus points under the new leadership. Roche shares currently trade at CHF332.4, approximately 8% below the CHF359.2 analyst consensus target.